SK Biopharmaceuticals Co., Ltd.
326030
Clasificación en acciones
#3730
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Precio por acción
$56.51
Capitalización bursátil
$4.43B
Cambio (1 día)
0.00%
Cambio (1 año)
-25.24%
País
KR
Comercio SK Biopharmaceuticals Co., Ltd. (326030)
Categoría
Healthcare
Historial del precio de la acción de SK Biopharmaceuticals Co., Ltd. (326030)
Precio más alto de cierre: $51.70 el 2026-10-01
Precio más bajo de cierre: $157.85 el 2020-07-01
Precio más bajo de cierre: $157.85 el 2020-07-01
Historial del precio de la acción de SK Biopharmaceuticals Co., Ltd. desde 2020 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2026 (TTM) | -22.47% |
| 2025 | 24.61% |
| 2024 | 2.56% |
| 2023 | 25.24% |
| 2022 | -33.05% |
| 2021 | -47.19% |
| 2020 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
